DB Biotech approached Pivotal Scientific earlier this year to help increase their presence within the biotech market. DB Biotech have an excellent portfolio of high-quality rabbit clonal antibodies which have been designed and manufactured using their novel and proprietary in-vitro cloning technology. This technology allows their monospecific clonal antibodies to be uniquely characterized by exceptional specificity, affinity, and avidity.
Once Pivotal Scientific had been appointed to help drive sales of DB Biotech an initial full audit of the company was carried out. This included an evaluation of their sales channels, marketing activities and the company structure. Upon review of their technology it was highlighted that DB Biotech have the capability to produce an antibody that is completely post-translationally modified and properly glycosylated. This allows the antibodies to be more stable than antibodies produced by traditional cellular systems. When used alongside novel technology to produce a specially targeted linear epitope for immunisation, and combined with proprietary in-vitro cloning technology to separate a monospecific immunoglobulin, the resulting antibody corresponding to a single clone of B lymphocytes is comparable in quality to its monoclonal analogue, but with the following advantages:
- Exceptional specificity recognizing the corresponding antigen at the concentration of ≥5ng
- Highest possible sensitivity, affinity and avidity
- Reliability on any tissue
- Cost-effective dilutions
- Special focus on difficult targets
Representing a new gold-standard in antibody development, DB Biotech’s CE certified antibodies are suitable for use in a number of applications including immunohistochemistry, western blotting, ELISA, immunoprecipitation, immunocytochemistry and flow cytometry.
The data collected from the company audit was analysed and the findings used to create a business plan which would determine the roadmap for DB Biotech to improve business efficiency, thereupon driving sales and brand awareness. It was identified that additional resources were required to assist in increasing sales therefore DB Biotech assigned Pivotal Scientific as their outsourced B2B and Sales and Marketing team.
Whilst working with DB Biotech, one key sales opportunity that Pivotal Scientific refined was the management of their distributor and OEM partners. Both companies worked together to implement a new distributor strategy which included restructuring the distributor network and ensuring that all distributors were supported with updated marketing materials. Furthermore, Pivotal Scientific used their own extensive database to identify and introduce DB Biotech to suitable OEM partners.
Currently we continue to develop DB Biotech’s overall brand image, website SEO & content writing, website rebuild, social media management, Google Ads and eblasts.
